Wound and injury recovery
7Community surgical/sports reports; unvalidated.
Skin & recoveryBlend
KLOW
GHK-Cu, BPC-157, TB-500, and KPV blend
Community reportsSkin appearance · recovery2
No FDA-approved KLOW blend; no verified clinical trial of this exact combination.
What does it do?
GHK-Cu, TB-500, BPC-157 and KPV blend marketed for repair and inflammation. No clinical study establishes whole-blend efficacy, optimal ratio or long-term safety.
Approved & studied uses
No established medical use is documented for this formulation.
Evidence limits
View research →Safety, stability, interactions, and efficacy of the exact blend.1
0 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Combination safety gap
Individual-component research cannot establish safety of the mixture.2
No FDA-approved KLOW blend; no verified clinical trial of this exact combination.
Molecular information
Amino-acid sequence
This blend contains multiple compounds and has no single amino-acid sequence.
GHK-Cu50 mgBPC-15710 mgTB-500 (label)10 mgKPV10 mg
LengthMultiple peptides
Molecular weight · DaNo single molecular weight
Formula, sequence notation & identity
Molecular formulaNo single molecular formula1
KLOW is a mixture, not a single molecule
Example: 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 + 10 mg KPV (80 mg total). Ratios and TB-500 identity require product-specific verification.
Pharmacokinetics
How long does it stay in the body?
There is no single half-life for a mixture. Component kinetics cannot be averaged into a validated blend curve, and no human combination PK study is cited.
What to expect
Study outcomes
Reported timelines
Reference & communityDays; 2–4 weeks
Community inflammation/healing reports; no predictable validated timeline.7
These are reported timelines, not a prediction of your response.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
The source hides 10 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Age range
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 23 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 30 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 29 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
The source hides 24 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Would recommend
The source hides 13 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
How discovered
The source hides 6 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Source & limitations
The source displays “5464 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Source corrections
Source labels are hypotheses; absence of studies cannot establish compatibility, and adding KPV does not prove lower injection risk.
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQ | 3.2 mg total (2 mg GHK-Cu, 400 mcg each TB500/KPV/BPC-157) | Once daily | Common Research ProtocolReference report | 4-6 weeks typical | 7 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source labels are hypotheses; absence of studies cannot establish compatibility, and adding KPV does not prove lower injection risk. Source tabs Injectable | |||||
| SubQ | 2 mg total (1.25 mg GHK-Cu, 250 mcg each TB500/KPV/BPC-157) | Once daily | Starter/Titration ProtocolReference report | 4-6 weeks typical | 7 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source labels are hypotheses; absence of studies cannot establish compatibility, and adding KPV does not prove lower injection risk. Source tabs Injectable | |||||
| SubQ | As above | 4-6 weeks on, 2-4 weeks off | Cycling ProtocolReference report | 4-6 weeks typical | 7 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source labels are hypotheses; absence of studies cannot establish compatibility, and adding KPV does not prove lower injection risk. Source tabs Injectable | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 4-6 weeks typical
- Break
- 2-4 weeks reported
Reported timing
Evening administration common but not studied
Side effects & safety
Combination safety gap
Individual-component research cannot establish safety of the mixture.
2Identity and amount uncertainty
The trade name alone is insufficient to identify component quantities or the TB-500 molecular form.
1Attribution is difficult
With multiple components, a perceived benefit or adverse effect cannot readily be assigned to one ingredient.
2Unstudied mixture
Contamination, variable formulation, injection reactions and copper accumulation.
Stop symptoms
Severe reaction/infection, allergy, weakness, worsening disease, nausea or jaundice.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
7 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
GLOW
Caution reportedDuplicate three ingredients.7
Reference report · Pep-Pedia label: Use CautionAnticoagulants
Caution reportedSource flags clotting/healing concerns.7
Reference report · Pep-Pedia label: Use CautionGrowth hormone
Avoidance reportedTheoretical growth-signaling concern.7
Reference report · Pep-Pedia label: Avoid CombinationImmunosuppressants
Caution reportedUncertain immune interaction.7
Reference report · Pep-Pedia label: Use CautionIpamorelin
Unverified pairingNo combination studies.7
Reference report · Evidence context: UnknownNAD+
Unverified pairingNo combination studies.7
Reference report · Evidence context: UnknownThe components with one another
Not establishedNo controlled human study of this named formulation establishes compatibility, synergy or interaction risk.21
Research contextNo matching interactions. Try another name or filter.
Reconstitution calculator
Enter your peptide amount and container size. Get a volume and a simple measurement scale.
Suggested final volume mL
Estimated water to add≈ mL
For dry powder, assuming negligible volume displacement. Use bacteriostatic water only if the formulation specifies it.
1 pen unit (one dial step)=
Amounts below are total blend mass. Ingredient amounts are listed separately.
| Pen units | Amount | Volume |
|---|
Ingredients per unit
Other simple scales
Convert a specific amount
Enter an amount to calculate its volume and device setting.
Calculation & assumptions
The suggestion favors a simple 1, 2, or 5 × power-of-ten amount per unit, then the largest final volume that fits. It does not choose a dose or a biologically suitable concentration.
The water estimate applies only to dry powder and assumes negligible powder displacement. Final solution volume, specified diluent, solubility, stability, sterility, cartridge compatibility, and working fill limits must be established separately. No allowance is made for priming or transfer losses.
V2 measurement specification ↗Bacteriostatic water: formulation instructions ↗Reconstitution
A total-mg label alone cannot determine the preparation or amount of each component.1
Composition first
Example: 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 + 10 mg KPV (80 mg total).1
No universal diluent or storage rule
The cited listing does not validate a BAC-water volume, combined chemical stability, sterility after preparation, or multidose beyond-use date.1
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
Pep-Pedia reports an 80 mg blend concentration example.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- 4 mL gives 20 mg/mL total blend concentration; the source discusses 2–5 mL volumes. · Reported storage: refrigerated for 4–6 weeks.
The source describes gentle mixing and avoiding vigorous shaking.
Component concentrations depend on the exact blend ratio. The source permits slight cloudiness without a validated product specification.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceThird-party testingReported appearanceReputable research supplierReported variationResearch-only statusReported variationBatch variabilityReported concernNo COA provided
7Vial sizes
80mg1
- GHK-Cu
- 50 mg
- BPC-157
- 10 mg
- TB-500 (label)
- 10 mg
- KPV
- 10 mg
Amounts are total blend mass. Formulas and ratios vary. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Refrigerated lifetime not established
The checked sources do not establish how long this research preparation remains stable and sterile after mixing.7
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Pen & syringe measurements Scales, capacity & references
Pen & syringe measurements
Device units measure volume. Concentration determines the amount in mg.
1 notch = 0.01 mL
Documented 1-unit V2 models
- One dial increment
- 1 unit
- Cartridge capacity
- 3 mL
- Maximum setting
- 60 units · 0.60 mL
Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.
1 unit = 0.01 mL
100 units = 1 mL
- 10 units
- 0.10 mL
- 30-unit capacity
- 0.30 mL
- 50 / 100-unit capacity
- 0.50 / 1 mL
Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.
Use the mL scale
mL syringes and calibrated pipettes
- 0.01 mL
- 10 µL
- 0.10 mL
- 100 µL
- Amount
- mL × mg/mL
Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.
3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.
Device references
AVERON V2 specifications ↗SilverLeaf V2 unit reference ↗FDA: syringe unit conversions ↗Specifications checked October 12, 2026.Research findings
No blend trialsSource context
Source labels are hypotheses; absence of studies cannot establish compatibility, and adding KPV does not prove lower injection risk.
Compound identity & other names
A market blend commonly combining GHK-Cu, BPC-157, TB-500, and KPV. The extra ingredient does not establish better tolerability or stronger effects. Exact composition must be read from the individual label.
Other names: Klow blend · Klow protocol · KLOW 80 · GHK-Cu BPC-157 TB-500 KPV · KLOW Protocol
No FDA-approved KLOW blend; no verified clinical trial of this exact combination.
How it may work
Proposed collagen, migration, growth-factor and NF-κB pathways; component evidence does not prove combination synergy.7
Total mass of the labeled blend
A checked catalog lists 50 mg GHK-Cu plus 10 mg each of BPC-157, TB-500, and KPV. Each constituent is only a fraction of the total.
1Combination claims remain untested
Pep-Pedia states that clinical trials have not examined this four-peptide combination. Individual-component findings do not demonstrate additive benefit or reduced injection reactions.
2Research areas and evidence gaps
- Safety, stability, interactions, and efficacy of the exact blend.
- Whether adding KPV changes clinical outcomes or tolerability.
- Market-wide consistency of formulation and molecular identity.
Community reports Unvalidated
Pep-Pedia describes daily use for inflammation, skin, and recovery discussions while acknowledging no combination trial.2
No control group, representative sample, or verified outcomes; ratios and products vary.
Search coverage and review status
No direct controlled trial of this named blend was identified in the targeted check. Component literature is retained separately from blend claims.
- Checked
- 2026-10-12
- Search
- KLOW peptide combination trial
- Catalog
- Pep-Pedia ↗ · 4 listed references retained
- Targeted search, not a systematic or exhaustive review.
- Retained bibliography entries marked Bibliography only have not been independently verified.
- Distinct URLs may refer to the same publication; component and formulation boundaries remain important.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1Rewerk KLOW 80 mg compositionComponent research or community information does not establish effects of this blend.Catalog checked
AI-PREPARED SUMMARY
Lists 50 mg GHK-Cu plus 10 mg each of BPC-157, TB-500, and KPV per vial. This is a nominal supplier specification, not clinical validation.
Total mass of the labeled blend
A checked catalog lists 50 mg GHK-Cu plus 10 mg each of BPC-157, TB-500, and KPV. Each constituent is only a fraction of the total.
2Pep-Pedia: klow community protocol referenceComponent research or community information does not establish effects of this blend.Community source checked
AI-PREPARED SUMMARY
Publishes community-style 2–3.2 mg daily blend schedules and explicitly notes absent combination trials. Reported schedules are not proven safe or effective.
Combination claims remain untested
Pep-Pedia states that clinical trials have not examined this four-peptide combination. Individual-component findings do not demonstrate additive benefit or reduced injection reactions.
3Individual Component Research - GHK-Cu (Multiple Studies)Component research or community information does not establish effects of this blend.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The cited evidence concerns GHK-Cu by itself; skin, wound and gene-expression findings cannot establish the four-component blend's effects.
Reported population / model
Human studies
Reported study details
Various protocols · 40+ years research
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. Component research or community information does not establish effects of this blend.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
4BPC-157 Limited Human Data (2020)Component research or community information does not establish effects of this blend.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: A small BPC-157 bladder-symptom pilot is described as having ten complete responses among twelve participants; it did not test KLOW.
Reported population / model
Human pilot
Reported study details
12 patients · Interstitial cystitis
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. Component research or community information does not establish effects of this blend.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5No Published Studies on KLOW CombinationComponent research or community information does not establish effects of this blend.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source identifies no published direct efficacy or safety study of the complete KLOW formulation.
Reported population / model
No clinical trials
Reported study details
No safety studies · No peer-reviewed research
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. Component research or community information does not establish effects of this blend.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6Two-Peptide Combinations Only (Various)Component research or community information does not establish effects of this blend.Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The card alludes to two-component animal work without an original link; it does not establish safety or efficacy of a four-component product.
Reported population / model
Limited research
Reported study details
BPC-157 + TB-500 · Animal models
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. Component research or community information does not establish effects of this blend.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Pep-Pedia: KLOW — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12